戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 mized to receive either placebo (n= 2031) or acadesine (0.1 mg x kg(-1) x min(-1); n=2012) by intrave
2  participants were randomized 1:1 to receive acadesine (0.1 mg/kg per minute for 7 hours) or placebo
3 id (twice the shed blood volume) plus either acadesine (5 mg/kg bolus + 1 mg/kg x 60 min, n = 10) or
4  h) and in cardioplegia solution (placebo or acadesine; 5 microg/ml).
5  perioperative and postoperative infusion of acadesine, a first-in-class adenosine-regulating agent,
6                                              Acadesine also reduced the use of ventricular-assistance
7 ents undergoing CABG surgery, treatment with acadesine before and during surgery can reduce early car
8                                          The acadesine benefit was similar among diverse subsets, and
9 refore, we questioned whether use of the ARA acadesine-by increasing interstitial adenosine concentra
10 hrough postoperative day 4 demonstrated that acadesine decreased by 89% the number of deaths from 13.
11  high-risk patients undergoing CABG surgery, acadesine did not reduce the composite of all-cause mort
12 cacy of the adenosine regulating agent (ARA) acadesine for reducing long-term mortality among patient
13 e placebo group and 76 of 1493 (5.1%) in the acadesine group (odds ratio, 1.01 [95% CI, 0.73-1.41]).
14 transient increase in serum uric acid in the acadesine group.
15 S: The Reduction in Cardiovascular Events by Acadesine in Patients Undergoing CABG (RED-CABG) trial,
16                                              Acadesine is the first therapy proven to be effective fo
17 randomized to receive placebo (n = 1,346) or acadesine (n = 1,352) by intravenous infusion (0.1 mg/kg
18 ar accident was not significantly reduced by acadesine (OR, 0.69; 95% Cl, 0.44-1.08; P=.10).
19  27.8% (15 of 54; placebo) to 6.5% (3 of 46; acadesine) (p = 0.006), with the principal benefit occur
20                     Fluid resuscitation with acadesine produced no adverse hemodynamic consequences a
21 he placebo group to 1.4% (1 death/71 MIs) in acadesine-treated patients (P=.003).
22                                              Acadesine treatment, however, reduced that mortality by
23 cidence of adverse events was similar in the acadesine vs placebo groups, with the exception of a tra
24                     After resuscitation with acadesine vs. vehicle, we observed the following: a) art
25 me conditions, the acute salutary effects of acadesine were probably overwhelmed by polymicrobial sep

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。